Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN20423 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | - |
| Part B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN20423 | DRUG | Administered per the protocol |
| Placebo | OTHER | Administered per the protocol |
Part A: Enrolls healthy participants Part B: Enrolls participants with atopic dermatitis Key Inclusion Criteria: Part A: 1. Is judged by the investigator to be in good health based on medical history, physical examination, vital signs, Electrocardiograms (ECGs), and laboratory safety testing at s...
Top 20 of 26 competitors
REGN20423 is an investigational small molecule drug being developed by Regeneron Pharmaceuticals for the treatment of atopic dermatitis. It is currently in Phase 1 clinical development and has not been approved by any regulatory agency. Regeneron is evaluating it in a first-in-human study that includes both healthy adult volunteers and adults with atopic dermatitis.
REGN20423 is being studied for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is an investigational therapy and is not approved for any indication. The ongoing Phase 1 trial enrolls adults with atopic dermatitis alongside healthy adult volunteers to evaluate the drug in a controlled, double-blind setting.
REGN20423 is being developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron is the sponsor of the Phase 1 first-in-human trial evaluating the drug in healthy volunteers and adults with atopic dermatitis.
REGN20423 is in Phase 1 clinical development. It is an investigational small molecule and has not received FDA approval. The single registered trial is a first-in-human Phase 1 study that is currently recruiting participants, with no completed trials reported for this asset.
REGN20423 is being evaluated in one clinical trial, NCT07527923, titled a first-in-human trial to assess REGN20423 in healthy adult participants and adult participants with atopic dermatitis. The Phase 1 study is recruiting, is randomized, double-blind, and controlled, and plans to enroll 144 participants across the United States and Belgium.
The REGN20423 Phase 1 trial, NCT07527923, enrolls adults 18 years of age and older of any sex, including healthy volunteers and participants with atopic dermatitis. It is a randomized, double-blind, controlled first-in-human study being conducted in the United States and Belgium, with a planned enrollment of 144 participants.